Health Care Professionals


Santhera is passionate about medical science and about developing new medical treatments for patients with rare and other diseases. Our focus is on the development of therapies for rare neuromuscular and pulmonary conditions with high unmet medical needs.

Our pipeline

Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases.

This section of the website is intended
to provide healthcare professionals with
information about Raxone® and other
products in Santhera’s pipeline.

I am a Healthcare Professional
I am not a Healthcare Professional